Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States

• DOI: 10.1161/atvbaha.116.308011
• Publication Date: 2016-09-23T03:18:36Z
• Authors: Steve Varvel; Joseph P. McConnell; Sotirios Tsimikas
• Keywords: Blood Glucose; Glycated Hemoglobin; Male; Databases, Factual; Cholesterol, LDL; Middle Aged; 3. Good health; 03 medical and health sciences; C-Reactive Protein; Sex Factors; 0302 clinical medicine; Cardiovascular Diseases; Nephelometry and Turbidimetry; Predictive Value of Tests; Reference Values; Risk Factors; Prevalence; Humans; Insulin; Female; Biomarkers; Aged; Lipoprotein(a)

Objective— Elevated lipoprotein(a) [Lp(a)] is a causal, independent risk factor for cardiovascular disease and aortic stenosis. We aimed to define the prevalence patient thresholds of elevated Lp(a) levels in United States. Approach Results— analyzed 532 359 subjects from 2 data sets: (1) 531 144 referral laboratory (2) 915 patients tertiary center. mass were measured by immunoturbidometric assays both centers expressed as mg/dL. At laboratory, median age (interquartile range) was 57.0 (46–67) years, 51.9% female. skewed rightward expected. The mean±SD 34.0±40.0 mg/dL, 17 (7–47) with range 0 907 at 75%, 80%, 90%, 95%, 99%, 99.9% percentiles >47, >60, >90, >116, >180, >245 respectively. >30 >50 mg/dL present 35.0% 24.0% subjects, respectively, center, 39.5% 29.2%, Females had higher mean (SD) (37.0 [42.7] versus 30.7 [36.7]; P <0.0001) (19 [8–53] 15 [7–42]; than males. Conclusions— This largest database assess distribution derived opposed general populations. fairly common, particularly care setting. These may inform consensus documents, guidelines, therapeutic cutoffs Lp(a)-mediated risk.